Can medical polymers move beyond biocompatibility?

The regulatory and compensation systems in place for medical devices not only incentivize companies to launch products made from materials that are already on the market, they essentially create disincentives for companies to do anything really new or novel.

That's the view of Michael Drues, a 20-plus-year veteran of the device industry with a PhD in biomedical engineering who began his career in R&D and over the years has worked on the device and regulatory sides of the industry. Drues, president of Vascular Sciences, will be delivering two presentations at the upcoming MedTech Polymers conference (Oct. 14-15, Houston), including the keynote address. To illustrate his point on innovation in the industry, a topic in his presentation, Drues lays out a hypothetical situation. ...

Read more